CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies
Comunicato Precedente
Comunicato Successivo
"CardiaCare's innovative solution has the potential to significantly disrupt the standard of care in the treatment of AFib and other arrhythmias with a non-invasive wearable that administers neuromodulation stimulation therapy. Multiple clinical studies are already under way as we push to bring this advancement in cardiac care to market," said Ken Nelson, Chairman.
"CardiaCare's novel approach to treating AFib using neuromodulation will be a paradigm shift for the millions of patients that have no alternatives to toxic drugs, cardioversion shock therapy, or invasive procedures. Solardis Health Ventures is proud to lead this round and support CardiaCare's mission to become the first therapeutic wearable for cardiac arrhythmia patients," added Amir Soltanianzadeh, Founder & Managing Partner of Solardis Health Ventures.
About CardiaCare
CardiaCare is a privately-held, Israel-based company developing a platform for both treating and monitoring cardiac arrhythmias such as Atrial Fibrillation. The venture was founded by cardiac arrhythmia specialist and entrepreneur, Amos Ziv, after over a decade of caring for and creating new therapies for patients with AFib. Website: https://my-CardiaCare.com
Logo - https://mma.prnewswire.com/media/2211091/CardiaCare_Logo.jpg
Media Contact:
Ofer Halbreich
CEO, CardiaCare
Email: [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/cardiacare-completes-seed-extension-raise-to-support-clinical-pilot-studies-301927954.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




